Bolt Biotherapeutics gains on promising data from cancer therapy trial
29/03/2023 22:29
** Shares of drug developer Bolt Biotherapeutics Inc
BOLT.O gain ~10% at $1.42 after market
** Company says an early-stage dose-escalation study of its
experimental cancer therapy, BDC-1001, showed anti-tumor
activity in the form of "multiple" partial responses and tumor
shrinkage, among others
** BDC-1001 was well tolerated at all dose levels, both as
monotherapy and in combination with Bristol-Myers Squibb's
BMY.N Opdivo - BOLT
** Data supports therapy's advancement into mid-stage
studies in some types of cancers such as breast, colorectal
gastroesophageal cancers, says company
** Therapy is being tested in patients with HER2-expressing
solid tumors
** Company also says it has entered into a clinical supply
agreement with Roche to evaluate cancer drug Perjeta in
combination with BDC-1001
** Bolt shares have fallen ~18% in the past six months, as
of last close
(Reporting by Raghav Mahobe)
((Raghav.Mahobe@thomsonreuters.com;))